F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.
Genentech, Inc., South San Francisco, California, USA.
Cancer Med. 2024 Aug;13(16):e70032. doi: 10.1002/cam4.70032.
The large real-world EHR dataset Flatiron has shown that race was not significantly associated with poorer survival in patients with DLBCL. Medicaid insurance status was significantly associated with poorer overall survival and time to second-line therapy or death due to any cause in patients with DLBCL aged <65 years.
大型真实世界电子健康记录数据集 Flatiron 表明,种族与 DLBCL 患者的生存状况较差并无显著相关性。在年龄<65 岁的 DLBCL 患者中,医疗补助保险状态与总体生存率较差以及二线治疗或任何原因导致的死亡时间显著相关。